Chimerix Chooses Merck As HIV Partner, Keeps Broad-Spectrum Antiviral
This article was originally published in The Pink Sheet Daily
The North Carolina-based start-up strikes a global deal for a Phase I HIV drug, which will allow it to fund late-stage trials on another lipid-antiviral conjugate.
You may also be interested in...
Once wary of the IPO market, the antiviral drug developer looks to public investors as it prepares to fund a Phase III trial for a well-regarded but unpartnered cytomegalovirus drug.
The termination of a Phase III trial for Abbott/Reata’s projected blockbuster bardoxolone is just one of several recent major blow-ups of a significant pharma/biotech collaboration. One analyst thinks narrow, short-term thinking by business development execs links all of the clinical letdowns.
Merck partners with on AiCuris on letermovir and other antiviral candidates for human cytomegalovirus (HCMV), marking the first development deal for the German drug developer, spun out from Bayer in 2006.